SUV, or standardized uptake value, is a number that reflects how aggressively a spot in your body is absorbing a radioactive tracer during a PET scan. A “high” SUV generally means that area is metabolically hyperactive, and while cancer is the most common clinical concern driving the scan, infection, inflammation, and even normal tissue variants can also produce strikingly elevated numbers. There is no single universal cutoff that separates dangerous from harmless, which makes interpreting a high SUV more nuanced than most patients expect when they first see the number on their report.
How the Number Is Calculated
Most PET scans in oncology use a tracer called FDG, a modified sugar molecule tagged with a small amount of radioactive fluorine. After injection, FDG travels through the bloodstream and gets taken up by cells that are hungry for glucose. Cancer cells tend to be extremely glucose-hungry because they divide rapidly and rely heavily on sugar metabolism. The scanner detects where the tracer concentrates and assigns each spot an SUV based on how much tracer accumulated there relative to what you would expect if the tracer spread evenly throughout your body. An SUV of 1.0 means a region absorbed exactly the amount you would predict from even distribution. An SUV of 10 means that spot absorbed roughly ten times the expected amount.
Research has shown that FDG uptake correlates with the expression of glucose transporters on cell surfaces and with enzymes that trap glucose inside cells. A study of pancreatic cancer found that SUV measured at one hour correlated with glucose transporter expression, while delayed imaging reflected the activity of a glucose-trapping enzyme called hexokinase-II.1Journal of Nuclear Medicine. Relationship Between Retention Index in Dual-Phase 18F-FDG PET, and Hexokinase-II and Glucose Transporter-1 Expression in Pancreatic Cancer In plain terms, the SUV is not just a random intensity reading. It reflects real biological activity at the molecular level.
What Counts as “High”
You will often hear that an SUV above 2.5 raises suspicion for malignancy, and that number does appear frequently in clinical guidelines as a rough screening threshold, especially for lung nodules. But calling any single number a universal dividing line oversimplifies the picture. Some slow-growing cancers produce SUVs well below 2.5, while some perfectly benign processes push the number above 10.
Radiologists typically compare a lesion’s SUV against a reference tissue, most often the liver. Normal liver SUV usually falls somewhere around 2 to 3 on the standard body-weight-normalized scale, though the exact number varies with the scanner, your blood glucose level, and the time elapsed after injection. A study looking at liver SUV across different scanner brands and cancer populations found that normalization method and glucose correction affected measurements enough to produce statistically significant differences between machines.2PubMed Central. Estimation of liver standardized uptake value in F18-FDG PET/CT scanning: impact of different malignancies, blood glucose level, body weight normalization, and imaging systems This is one reason your doctor looks at the SUV in context rather than treating it as a standalone verdict. When a lesion lights up well above the liver background, concern rises. When it sits near or below the liver, the probability of aggressive malignancy drops, though it does not disappear entirely.
Why a High SUV Does Not Always Mean Cancer
Activated immune cells are glucose-hungry too, which is why infections and inflammatory conditions frequently produce high SUVs that mimic malignancy on PET scans. Tuberculosis, fungal infections, sarcoidosis, and even the tissue changes that follow surgery or radiation therapy can all produce intense tracer uptake.3PubMed Central. False positive and false negative FDG-PET scans in various thoracic diseases A review of infectious and inflammatory mimics in oncology PET imaging concluded that caution is essential to avoid misdiagnosing benign processes as cancer, and that combining the PET findings with CT anatomy and patient history helps sort things out, though sometimes additional workup is unavoidable.4PubMed Central. The impact of infection and inflammation in oncologic (18)F-FDG PET/CT imaging
Brown fat is another well-known false-positive generator. This metabolically active tissue burns calories to generate heat and takes up FDG avidly, producing symmetrical areas of high uptake in the neck, shoulders, and along the spine. A large retrospective analysis of over 15,000 PET scans confirmed that brown fat can exhibit high FDG uptake and interfere with scan interpretation.5PubMed Central. Factors influencing brown fat activation in FDG PET/CT: a retrospective analysis of 15,000+ cases Brown fat activation is more common in women, younger patients, and people scanned during cold weather. The pattern is usually recognizable by its symmetry and characteristic locations, including the neck, axillae, and paravertebral regions.6Journal of Nuclear Medicine. Patterns of 18F-FDG Uptake in Adipose Tissue and Muscle: A Potential Source of False-Positives for PET Experienced radiologists spot this pattern quickly, but if you are reading your own report and see hot spots in the shoulders or neck described as “likely brown fat,” that is what is going on.
Technical Factors That Shift the Number
SUV is supposed to standardize measurements across patients, but several real-world variables push the number around. Blood glucose level at the time of injection is among the most important. When blood sugar is elevated, ordinary glucose competes with the FDG tracer for entry into cells, which can lower the apparent SUV in tumors and raise it in the liver and blood pool. A meta-analysis pooling over 20,000 individual SUV measurements found that higher blood glucose correlated with lower SUV in the brain and muscle, higher SUV in the liver and blood pool, and no significant effect on tumor SUV until glucose climbed above 200 mg/dL, at which point tumor uptake dropped significantly.7PubMed. Effect of blood glucose level on standardized uptake value (SUV) in (18)F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements
This matters practically because most imaging centers require you to fast before a PET scan and will check your blood sugar before injecting the tracer. If glucose is too high, the scan may be rescheduled. A study of patients with bloodstream infections found that the rate of detecting a true infection focus on PET dropped sharply when blood glucose exceeded roughly 144 mg/dL and fell further above 200 mg/dL.8Journal of Nuclear Medicine. Importance of Blood Glucose Management Before 18F-FDG PET/CT in 322 Patients with Bacteremia of Unknown Origin In other words, poorly controlled blood sugar does not just change the number on the report; it can genuinely hide disease.
Body weight, uptake time (how long you wait between injection and scanning), and the scanner hardware itself also contribute to variability. Background liver and mediastinal SUVs were shown to decrease with longer uptake times, and body weight affected standard SUV in the liver but had less effect when lean-body-mass normalization was used instead.9PubMed Central. Multivariate analysis of various factors affecting background liver and mediastinal standardized uptake values This is one reason reports sometimes list SUV corrected for lean body mass alongside the standard body-weight version.
SUVmax, SUVmean, and SUVpeak
Your PET report might list more than one SUV variant, and they are not interchangeable. SUVmax is the single hottest pixel in a lesion. It is easy to measure and widely used, but because it relies on a single point, it can be noisy, especially in small tumors. SUVmean averages the uptake across a defined region, which smooths out noise but depends on how the borders of that region are drawn. SUVpeak averages uptake within a small fixed-volume sphere centered on the hottest area, making it a compromise between the two.
A study comparing these metrics across different reconstruction algorithms found that SUVpeak had the highest reproducibility. The variability of SUVmax and SUVmean increased for lesions smaller than about 5 milliliters, while SUVpeak stayed more stable.10PubMed. Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? – Variability induced by different SUV measurements and varying reconstruction methods For most clinical decisions, SUVmax is still the default because it is the simplest to extract and compare across time points. But when clinicians are tracking treatment response in research or clinical trials, SUVpeak is increasingly favored for its consistency.
What a High SUV Suggests About Tumor Biology
Within confirmed cancers, higher SUVs generally correlate with more aggressive disease. The relationship is not perfect, but it is consistent enough across tumor types that many oncologists treat the initial SUV as one piece of prognostic information.
In breast cancer, a meta-analysis covering 25 studies and over 1,600 patients found a moderate positive correlation between SUVmax and Ki-67, a protein marker of how fast tumor cells are dividing.11PubMed Central. Associations Between PET Parameters and Expression of Ki-67 in Breast Cancer A separate study confirmed that higher-grade breast tumors had higher mean SUVmax values, and that tumors with high Ki-67 expression had a mean SUVmax roughly 12 compared with about 7 for low Ki-67 tumors.12PubMed Central. Correlation of Maximum Standardized Uptake Values in 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Scan with Immunohistochemistry and Other Prognostic Factors in Breast Cancer In triple-negative breast cancer specifically, SUVmax and Ki-67 were significantly correlated, and tumors tended to be more poorly differentiated as both values climbed.13PubMed. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer
The pattern holds in other cancers as well. In non-small-cell lung cancer, survival decreased as the SUVmax of both the primary tumor and its regional lymph nodes went up, with each unit increase in SUV translating to a small but statistically significant bump in hazard.14The Annals of Thoracic Surgery. Measurement of Tumor and Lymph Node Standardized Uptake Value Predicts Survival in Nonsmall Cell Lung Cancer In diffuse large B-cell lymphoma, patients whose pretreatment SUVmax reached 30 or higher had three-year overall survival around 71% compared with 86% for those below that cutoff.15PubMed. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma In endometrial cancer, patients with SUVmax above roughly 13 had significantly lower disease-free survival.16PubMed. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer
None of these thresholds are used in isolation to make treatment decisions. They add a metabolic dimension to the staging picture alongside tumor size, spread, biopsy results, and genetic markers. Think of the SUV as one voice in a committee rather than a judge issuing a ruling.
Using SUV Changes to Track Treatment Response
A single SUV at diagnosis tells you something about the tumor’s biology, but the change in SUV during or after treatment is often more clinically useful. If a lesion’s SUV drops dramatically after a few cycles of chemotherapy, that is a strong signal the treatment is working. If it barely budges or rises, the treatment may need to change.
Formal response criteria exist for this purpose. The most widely used metabolic criteria, called PERCIST, defines response thresholds based on changes in SUL (a lean-body-mass-corrected version of SUV) measured within the hottest tumor. A study comparing PERCIST with the older size-based RECIST criteria in non-small-cell lung cancer found that only the metabolic PERCIST criteria independently predicted disease-free survival on multivariate analysis.17PubMed Central. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST) In practical terms, metabolic changes visible on PET often show up earlier than size changes visible on CT, which can speed up the decision to switch a failing regimen.
When SUV Goes Up During Immunotherapy
Immunotherapy has introduced a confounding wrinkle into SUV interpretation. Drugs like pembrolizumab work by unleashing the immune system against tumors, and in the process, immune cells flood into tumor sites and surrounding tissue. Those activated immune cells gobble up glucose just as cancer cells do, which can temporarily push the SUV higher and make lesions look bigger on PET even though the treatment is actually working. This phenomenon is called pseudoprogression.
A case report described a patient with metastatic bladder cancer whose PET scan after pembrolizumab showed increased size and metabolic activity in metastatic lesions, suggesting the disease was getting worse. A follow-up scan eight weeks later revealed significant regression, confirming pseudoprogression rather than true treatment failure.18Molecular Imaging and Radionuclide Therapy. Pseudoprogression Shown on 18F-FDG PET/CT After Pembrolizumab Treatment in a Case of Metastatic Bladder Cancer This is why oncologists increasingly order confirmation scans before abandoning an immunotherapy regimen that appears to fail on a single PET. An early rise in SUV after immunotherapy is not necessarily bad news, and jumping to conclusions based on one scan can lead to premature treatment changes.
Dual-Time-Point Imaging to Sort Out Ambiguous Spots
When a lesion has an SUV in the gray zone, neither clearly benign nor obviously malignant, radiologists sometimes use a dual-time-point technique. Instead of scanning once at the usual 60 minutes after injection, they scan again at a later time, typically around two hours. The idea rests on a biological difference: cancer cells tend to keep accumulating FDG over time, so their SUV rises on the delayed scan, while benign inflammatory lesions tend to plateau or decline.
A study testing this approach found that malignant lesions increased their SUV by about 19% on the delayed scan, while benign lung nodules showed a slight decrease of about 6%. Inflammatory lesions from radiation therapy and prosthesis-related irritation stayed essentially flat.19Journal of Nuclear Medicine. Dual Time Point 18F-FDG PET Imaging for Differentiating Malignant from Inflammatory Processes The technique has also been validated for solitary pulmonary nodules with initial SUVmax below 2.5, where the standard threshold fails to provide a clear answer.20PubMed. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5 Dual-time-point imaging is not ordered routinely for every scan, but it is a useful tool when a single time point leaves genuine diagnostic uncertainty.
The same delayed-scan principle has found applications beyond cancer. In suspected cardiac sarcoidosis, where inflammation of the heart muscle needs to be detected or ruled out, delayed FDG PET acquisition improves detection accuracy compared with early scans, partly because background blood-pool activity washes out over time and inflammatory foci become more visible.21PubMed. Diagnostic values of delayed additional FDG PET/CT scan in the evaluation of cardiac sarcoidosis
Beyond FDG and the Rise of Specialized Tracers
FDG remains the workhorse tracer in oncology PET, but it is essentially a general metabolic probe. It lights up anything that consumes a lot of glucose, which is why cancer, infection, and brown fat can all look similar. Newer tracers are designed to bind specific molecular targets, making SUV interpretation more disease-specific.
PSMA-targeted tracers, for instance, bind to a protein overexpressed on prostate cancer cells. A high SUV on a PSMA PET scan is far more specific to prostate cancer than a high SUV on an FDG scan would be, because PSMA is not broadly expressed on inflammatory or metabolically active normal tissues the way glucose transporters are. DOTATATE tracers target somatostatin receptors, which are densely expressed on neuroendocrine tumors. In these specialized scans, positivity is often defined relative to liver uptake, such as a lesion SUVpeak at least 1.5 times the liver’s mean SUV.22PubMed. Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC)
These receptor-specific tracers have added a therapeutic dimension as well. When a DOTATATE or PSMA scan shows high uptake in tumor lesions, it suggests those lesions could be targeted with a radioactive treatment version of the same molecule, delivering radiation directly to the cancer cells that express the receptor. Scoring systems have been developed to grade the intensity of tracer uptake on these scans, helping clinicians determine which patients are candidates for such targeted radionuclide therapy.23Nuclear Medicine Communications. Assessing Krenning’s score on 68 Ga-DOTATATE PET-CT and miPSMA score on 68 Ga-PSMA-11 PET-CT in TENIS In these contexts, a high SUV is not just diagnostic information; it is the gateway to a specific treatment option.
Scanner Differences and the Push for Standardization
One of the less visible problems with SUV is that the same patient scanned on two different PET machines might get noticeably different numbers. Differences in detector technology, image reconstruction algorithms, and calibration routines all contribute. This is especially problematic when patients are followed over time at different facilities, or when multi-center clinical trials need to pool SUV data.
Efforts to harmonize PET quantification have been ongoing for years. Professional organizations have published protocols specifying acquisition settings, reconstruction parameters, and phantom-based quality checks intended to bring different scanners into closer agreement. The convergence of harmonization frameworks, improvements in digital PET detector technology, and physics-led quality control define the current phase of the field, with emerging tools including AI-driven methods to further reduce inter-scanner variability.24ScienceDirect. Standardization and quality control in PET imaging: Advances, challenges, and clinical implications For patients, the practical upshot is simple: if your treatment team is comparing today’s PET with an earlier one, it helps to have both scans done at the same center on the same machine, or at least on a machine enrolled in the same harmonization program.